{"DataElement":{"publicId":"6160137","version":"2","preferredName":"Overall Lesion Response irRC Measurable Category","preferredDefinition":"Text term to represent the derived overall disease response based on changes in tumor burden of index and new, measurable lesions using the  Immune-Related Response Criteria (irRC) criteria.","longName":"OVR_LES_RESP_irRC_CAT","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"2188872","version":"1","preferredName":"Overall Lesion Response","preferredDefinition":"Information relating to the overall lesion response.","longName":"OVERALL_LES_RESP","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2206600","version":"1","preferredName":"Overall Lesion","preferredDefinition":"Including everything.:(LEE-zhun) An area of abnormal tissue change.","longName":"C25605:C3824","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Overall","conceptCode":"C25605","definition":"Including everything.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lesion","conceptCode":"C3824","definition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-FBC1-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177336","version":"1","preferredName":"Response","preferredDefinition":"Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.","longName":"Response","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-528C-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":"Denise Warzel updated Definition by seraching NCI Thesaurus in Admin tool.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"irRECIST: Immune-related Response Evaluation Criteria in Solid Tumours (RECIST)-2013","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E49C180D-8D57-0916-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-10-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-10-05","modifiedBy":"GDEEN","dateModified":"2024-02-23","changeDescription":"8/7/18 jk added irRECIST CSI.  8/30/17 tt transferred context, added registration status and CSI per Round 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6161683","version":"1","preferredName":"irRC Measurable Overall Response Category","preferredDefinition":"A set of response criteria designed to capture additional response patterns observed with immune therapy beyond those described by Response Evaluation Criteria in Solid Tumors (RECIST) or WHO criteria._Capable of being measured._An assessment of the overall response of the disease to the therapy._A grouping of items based on some commonality or by user defined characteristics.","longName":"6161683v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"4","maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"irCR","valueDescription":"irCR (Immune-Related Response Criteria)","ValueMeaning":{"publicId":"6161693","version":"1","preferredName":"irCR (Immune-Related Response Criteria)","longName":"6161693","preferredDefinition":"Complete disappearance of all lesions (whether measurable or not, and no new lesions); confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-Related Response Criteria Complete Response","conceptCode":"C148193","definition":"Complete disappearance of all lesions (whether measurable or not, and no new lesions); confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"691F4496-0B50-378D-E053-F662850AA125","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"691F4496-0B68-378D-E053-F662850AA125","beginDate":"2018-04-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","deletedIndicator":"No"},{"value":"irPD","valueDescription":"irPD (Immune-Related Response Criteria)","ValueMeaning":{"publicId":"6161694","version":"1","preferredName":"irPD (Immune-Related Response Criteria)","longName":"6161694","preferredDefinition":"Increase in tumor burden greater than or equal to 25 percent relative to nadir (minimum recorded tumor burden); confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-Related Response Criteria Progressive Disease","conceptCode":"C148196","definition":"Increase in tumor burden greater than or equal to 25 percent relative to nadir (minimum recorded tumor burden); confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"691F4496-0B75-378D-E053-F662850AA125","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"691F4496-0B8D-378D-E053-F662850AA125","beginDate":"2018-04-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","deletedIndicator":"No"},{"value":"irPR","valueDescription":"irPR (Immune-Related Response Criteria)","ValueMeaning":{"publicId":"6161695","version":"1","preferredName":"irPR (Immune-Related Response Criteria)","longName":"6161695","preferredDefinition":"Decrease in tumor burden greater than or equal to 50 percent relative to baseline confirmed by a consecutive assessment at least 4 weeks after first documentation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-Related Response Criteria Partial Response","conceptCode":"C148194","definition":"Decrease in tumor burden greater than or equal to 50 percent relative to baseline confirmed by a consecutive assessment at least 4 weeks after first documentation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"691F4496-0B9A-378D-E053-F662850AA125","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"691F4496-0BB2-378D-E053-F662850AA125","beginDate":"2018-04-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","deletedIndicator":"No"},{"value":"irSD","valueDescription":"irSD (Immune-Related Response Criteria)","ValueMeaning":{"publicId":"6161696","version":"1","preferredName":"irSD (Immune-Related Response Criteria)","longName":"6161696","preferredDefinition":"Not meeting criteria for irCR or irPR, in absence of irPD.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-Related Response Criteria Stable Disease","conceptCode":"C148195","definition":"Not meeting criteria for irCR or irPR, in absence of irPD.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"691F4496-0BBF-378D-E053-F662850AA125","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"691F4496-0BD8-378D-E053-F662850AA125","beginDate":"2017-10-12","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6161682","version":"1","preferredName":"Immune-Related Response Criteria Measurable Overall Response Category","preferredDefinition":"A set of response criteria designed to capture additional response patterns observed with immune therapy beyond those described by Response Evaluation Criteria in Solid Tumors (RECIST) or WHO criteria.:Capable of being measured.:An assessment of the overall response of the disease to the therapy.:A grouping of items based on some commonality or by user defined characteristics.","longName":"C148192:C37894:C96613:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-Related Response Criteria","conceptCode":"C148192","definition":"A set of response criteria designed to capture additional response patterns observed with immune therapy beyond those described by Response Evaluation Criteria in Solid Tumors (RECIST) or WHO criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Measurable","conceptCode":"C37894","definition":"Capable of being measured.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Overall Response","conceptCode":"C96613","definition":"An assessment of the overall response of the disease to the therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"691BD3EB-0213-3970-E053-F662850A163C","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"irRC: Immune-Related Response Criteria-2009","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"691BD3EB-0224-3970-E053-F662850A163C","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"KNABLEJ","dateModified":"2018-10-23","changeDescription":"10/23/18 jk chg reg status to Standard for RECIST defined PV list; do not add PVs without checking latest version of guideline.  4/5/18 jk created for DCI study and immune RECIST FG activities.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5635300","version":"1","longName":"Case Report Form (CRF) Modules","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"5635324","version":"1","longName":"RECIST","context":"NCI Standards"},{"publicId":"6160006","version":"1","longName":"irRC","context":"NCI Standards"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"irRC Overall response","type":"Preferred Question Text","description":"irRC Overall response","url":null,"context":"NCI Standards"},{"name":"irRC","type":"Alternate Question Text","description":"Overall response","url":null,"context":"NCI Standards"}],"origin":"irRC: Immune-Related Response Criteria-2009","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"78D0CCF3-2899-0DD9-E053-F662850AA6F6","latestVersionIndicator":"Yes","beginDate":"2018-10-22","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-10-22","modifiedBy":"TAYLORT","dateModified":"2018-10-22","changeDescription":"10-22-18 Registration status changed to Standard/TMT. 10/22/18 jk versioned to chg SN from system-generated to text.  10/19/18 jk removed dup terms in LN. 10/9/18 tt changed question text to 1st word upper case. 4/2/18 jk created for DCI study and immune RECIST FG activities.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}